CD163 and ovarian cancer: We have previously shown that TAM in ovarian cancer ascites can be stratified into subsets based on the expression of the surface markers CD163 and CD206 (encoded by the MRC1 gene), both of which show a high degree of variance among patients (1–94% CD163+ or CD206+ of the CD14+ TAM population) (8).